Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) Gross Margin (2016 - 2025)

Utah Medical Products has reported Gross Margin over the past 16 years, most recently at 58.2% for Q4 2025.

  • Quarterly results put Gross Margin at 58.2% for Q4 2025, up 7.0% from a year ago — trailing twelve months through Dec 2025 was 57.12% (down 191.0% YoY), and the annual figure for FY2025 was 57.12%, down 191.0%.
  • Gross Margin for Q4 2025 was 58.2% at Utah Medical Products, up from 57.11% in the prior quarter.
  • Over the last five years, Gross Margin for UTMD hit a ceiling of 64.21% in Q3 2021 and a floor of 56.21% in Q2 2025.
  • Median Gross Margin over the past 5 years was 60.14% (2023), compared with a mean of 60.11%.
  • Biggest five-year swings in Gross Margin: soared 543bps in 2021 and later crashed -434bps in 2023.
  • Utah Medical Products' Gross Margin stood at 62.82% in 2021, then fell by -2bps to 61.34% in 2022, then dropped by -6bps to 57.55% in 2023, then grew by 1bps to 58.13% in 2024, then grew by 0bps to 58.2% in 2025.
  • The last three reported values for Gross Margin were 58.2% (Q4 2025), 57.11% (Q3 2025), and 56.21% (Q2 2025) per Business Quant data.